#RLYB

@newsen.bsky.social

2 days ago

Investigating Fairness of Shareholder Transactions in EWCZ, STEL, RLYB, and CTRA This article examines whether EWCZ, STEL, RLYB, and CTRA are securing equitable deals for their shareholders amidst ongoing investigations by Halper Sadeh LLC.

Investigating Fairness of Shareholder Transactions in EWCZ, STEL, RLYB, and CTRA #USA #New_York #EWCZ #STEL #RLYB

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? {"summary":"","positive":[],"negative":[],"faq":[]}

#AES #RLYB #VRME Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/AES/are-rlyb-vrme-a...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? {"summary":"","positive":[],"negative":[],"faq":[]}

#KW #AES #RLYB Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/KW/are-kw-aes-rlyb-...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement Rallybio (Nasdaq: RLYB) and Candid Therapeutics have agreed to merge, with the combined company to operate as Candid Therapeutics (Nasdaq: CDRX). The deal includes an oversubscribed private Financing of over $505 million and pro-forma cash of approximately $700 million expected to fund operations through 2030.The Transaction is expected to close in mid-2026, is subject to customary closing conditions, and pre-Transaction Rallybio equityholders are expected to own approximately 3.65% of the combined company.

#RLYB Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

www.stocktitan.net/news/RLYB/rallybio-corpo...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program Rallybio (Nasdaq: RLYB) has received a $12.5 million equity milestone payment from Recursion following the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor being developed for hypophosphatasia (HPP).This payment is part of a previously announced agreement where Rallybio sold its interest in the REV102 program to Recursion for up to $25 million. The company remains eligible for an additional $5 million milestone payment upon Phase 1 clinical study initiation, plus low single-digit royalties on future net sales.The non-dilutive capital extends Rallybio's cash runway through 2027, strengthening its financial position as it awaits topline data from the RLYB116 confirmatory PK/PD study.

#RLYB Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

www.stocktitan.net/news/RLYB/rallybio-recei...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates Rallybio (NASDAQ:RLYB) reported Q2 2025 financial results and significant business updates. The company sold its interest in REV102 to Recursion Pharmaceuticals for up to $25 million, including a $7.5 million upfront equity payment. The deal extends cash runway into mid-2027.Key financial metrics include a net loss of $9.7 million ($0.22 per share), reduced from $16.2 million in Q2 2024. R&D expenses decreased to $6.1 million from $12.9 million year-over-year. Cash position stands at $45.7 million as of June 30, 2025.The company's lead program RLYB116 entered a confirmatory PK/PD study, with data readouts expected in Q3 and Q4 2025. However, Rallybio discontinued the RLYB212 program for FNAIT prevention due to inadequate dose concentration achievements in Phase 2 trials.

#RLYB Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/RLYB/rallybio-repor...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Rallybio's $25M REV102 Sale to Recursion Promises First Oral Treatment for Rare Bone Disease $25M deal includes $7.5M upfront payment, extending cash runway to 2027. First potential oral treatment for hypophosphatasia (HPP) advances. See milestone details.

#RLYB Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

www.stocktitan.net/news/RLYB/rallybio-sells...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Rallybio's $5B Market Opportunity: New Phase 1 Trial Targets Two Untreated Rare Blood Disorders First-in-class C5 inhibitor begins crucial testing for rare blood disorders. Weekly subcutaneous dosing could transform treatment landscape. See trial timeline.

#RLYB Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

www.stocktitan.net/news/RLYB/rallybio-initi...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates Rallybio (NASDAQ: RLYB) reported Q1 2025 financial results and business updates. The company is advancing RLYB116 into a confirmatory PK/PD study in Q2 2025, with data readouts expected in H2 2025. Financial highlights include $54.5M in cash providing runway into H1 2027, revenue of $0.2M, and reduced net loss of $9.4M ($0.21/share) compared to $19.0M ($0.47/share) in Q1 2024. The company is implementing a 40% workforce reduction (9 positions) with expected charges of $1.7M. R&D expenses decreased to $5.7M from $12.9M, while G&A expenses reduced to $4.2M from $6.9M. Notable developments include discontinuation of RLYB212 program for FNAIT, ongoing IND-enabling studies for REV102, and continued evaluation of RLYB332 for iron overload diseases.

#RLYB Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/RLYB/rallybio-repor...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Rallybio Secures 2-Year Cash Runway as Multiple Drug Trials Advance Biotech firm Rallybio reports $65.5M cash position, advancing key drug trials RLYB212 and RLYB116. Q4 developments include J&J collaboration and pipeline expansion.

#RLYB Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/RLYB/rallybio-repor...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Rallybio's RLYB212 Enters Crucial Phase 2 Trial: Revolutionary Protection for At-Risk Pregnancies Rallybio initiates Phase 2 trial of RLYB212 for preventing pregnancy complications, with key data expected Q2-Q3 2025. European study targets FNAIT risk.

#RLYB Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

www.stocktitan.net/news/RLYB/rallybio-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Rallybio Advances Rare Disease Pipeline: Phase 2 FNAIT Trial Launch, Key Programs Progress Rallybio makes strides in rare disease therapeutics with RLYB212 Phase 2 FNAIT prevention trial, RLYB116 manufacturing improvements, and promising REV102 biomarker data for HPP treatment.

#RLYB Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

www.stocktitan.net/news/RLYB/rallybio-highl...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Rallybio's ASH Data Shows Breakthrough Potential in Blood Disorder Treatments, Strong Preclinical Results Rallybio presents compelling preclinical data for RLYB212 and RLYB332 at ASH, showing promising efficacy in pregnancy-related blood disorders and iron overload conditions.

#RLYB Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

#investing #stocks #news

www.stocktitan.net/news/RLYB/rallybio-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Rallybio's RLYB116 Shows Stronger-Than-Reported Efficacy in New Biomarker Analysis | RLYB Stock News Rallybio reveals RLYB116 achieved 10x better complement inhibition than initially measured. Manufacturing improvements made as company prepares for 2025 clinical studies.

#RLYB Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

#investing #stocks #StockMarket

www.stocktitan.net/news/RLYB/rallybio-to-in...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#RLYB Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

www.stocktitan.net/news/RLYB/rallybio-annou...

1 0 0 0

StockTitan

@stocktitan.net

1 year ago

#RLYB Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

www.stocktitan.net/news/RLYB/rallybio-to-pr...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#RLYB Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

www.stocktitan.net/news/RLYB/rallybio-to-pr...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#RLYB Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

www.stocktitan.net/news/RLYB/rallybio-annou...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #RLYB ) Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

#StockMarket #News

1 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #RLYB ) Rallybio to Present at Upcoming Investor Conferences

#StockMarket #News

1 0 0 0

Posts tagged #RLYB